Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2015, Article ID 729451, 7 pages
http://dx.doi.org/10.1155/2015/729451
Research Article

Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A “Real-Life” Study

1Unidad de Medicina Familiar y Comunitaria, Hospital Son Llàtzer, Palma de Mallorca, Spain
2Unidad de Enfermedades Autoinmunes, Hospital Clínico San Cecilio, Granada, Spain
3Servicio de Medicina Interna, Hospital Son Llàtzer, Palma de Mallorca, Spain
4Biomedical Research Institute, ibs. GRANADA, University Hospitals in Granada, University of Granada, Spain
5Servicio de Reumatología, Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain

Received 4 March 2015; Revised 15 May 2015; Accepted 19 May 2015

Academic Editor: Jun Iwamoto

Copyright © 2015 Miguel Ortego-Jurado et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. M. Spies, C. Strehl, M. C. Van Der Goes, J. W. J. Bijlsma, and F. Buttgereit, “Glucocorticoids,” Best Practice and Research: Clinical Rheumatology, vol. 25, no. 6, pp. 891–900, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. R. S. Weinstein, “Clinical practice: glucocorticoid-induced bone disease,” The New England Journal of Medicine, vol. 365, no. 1, pp. 62–70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Grossman, R. Gordon, V. K. Ranganath et al., “American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis,” Arthritis Care & Research, vol. 62, no. 11, pp. 1515–1526, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Briot, B. Cortet, C. Roux et al., “2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis,” Joint Bone Spine, vol. 81, no. 6, pp. 493–501, 2014. View at Publisher · View at Google Scholar
  5. M. Ishijima, Y. Sakamoto, M. Yamanaka et al., “Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women,” Calcified Tissue International, vol. 85, no. 5, pp. 398–404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. S. Carmel, A. Shieh, H. Bang, and R. S. Bockman, “The 25(OH)D level needed to maintain a favorable bisphosphonate response is 33 ng/ml,” Osteoporosis International, vol. 23, no. 10, pp. 2479–2487, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Peris, A. Martínez-Ferrer, A. Monegal, M. J. Martínez de Osaba, A. Muxi, and N. Guañabens, “25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis,” Bone, vol. 51, no. 1, pp. 54–58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Ortego-Jurado, R. Ríos-Fernández, J. L. Callejas-Rubio, M. Á. Gonzalez-Gay, and N. Ortego-Centeno, “Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy,” Osteoporosis International, vol. 25, pp. 2157–2158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Mazzaferro, D. Goldsmith, T. E. Larsson, Z. A. Massy, and M. Cozzolino, “Vitamin D metabolites and/or analogs: which D for which patient?” Current Vascular Pharmacology, vol. 12, no. 2, pp. 339–349, 2014. View at Google Scholar
  10. A. Jetter, A. Egli, B. Dawson-Hughes et al., “Pharmacokinetics of oral vitamin D3 and calcifediol,” Bone, vol. 59, pp. 14–19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. R. P. Heaney, “The nutrient problem,” Nutrition Reviews, vol. 70, no. 3, pp. 165–169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Bouillon, N. M. van Schoor, E. Gielen et al., “Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 8, pp. E1283–E1304, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Deane, L. Constancio, I. Fogelman, and G. Hampson, “The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis,” BMC Musculoskeletal Disorders, vol. 8, article 3, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Vieth, “Why the minimum desirable serum 25-hydroxyvitamin D level should be 75 nmol/L (30 ng/ml),” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 25, no. 4, pp. 681–691, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Mezquita Raya, M. Muñoz Torres, F. López Rodríguez et al., “Prevalence of vitamin D deficiency in populations at risk for osteoporosis: impact on bone integrity,” Medicina Clinica, vol. 119, no. 3, pp. 85–89, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. C. López-Robles, R. Rios-Fernández, J. L. Callejas-Rubio, and N. Ortego-Centeno, “Vitamin D deficiency in a cohort of patients with systemic lupus erythematous from the South of Spain,” Lupus, vol. 20, no. 3, pp. 330–331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Rios-Fernandez, J. L. Callejas-Rubio, C. Fernandez-Roldan et al., “Bone mass and vitamin D in patients with systemic sclerosis from two Spanish regions,” Clinical and Experimental Rheumatology, vol. 30, pp. 905–911, 2012. View at Google Scholar
  18. P. Saneei, A. Salehi-Abargouei, and A. Esmaillzadeh, “Serum 25-hydroxy vitamin D levels in relation to body mass index: a systematic review and meta-analysis,” Obesity Reviews, vol. 14, no. 5, pp. 393–404, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. T. J. Hahn, L. R. Halstead, and J. G. Haddad Jr., “Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy,” Journal of Laboratory and Clinical Medicine, vol. 90, no. 2, pp. 399–404, 1977. View at Google Scholar · View at Scopus
  20. D. M. Slovik, R. M. Neer, J. L. Ohman et al., “Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patients,” Clinical Endocrinology, vol. 12, no. 3, pp. 243–248, 1980. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. E. Davidson, K. Z. Walker, and H. Truby, “Do glucocorticosteroids alter vitamin D status? A systematic review with meta-analyses of observational studies,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 3, pp. 738–744, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. A. L. Skversky, J. Kumar, M. K. Abramowitz, F. J. Kaskel, and M. L. Melamed, “Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001–2006,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 12, pp. 3838–3845, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Akeno, A. Matsunuma, T. Maeda, T. Kawane, and N. Horiuchi, “Regulation of vitamin D-1α-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney,” Journal of Endocrinology, vol. 164, no. 3, pp. 339–348, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Kurahashi, A. Matsunuma, T. Kawane, M. Abe, and N. Horiuchi, “Dexamethasone enhances vitamin D-24-hydroxylase expression in osteoblastic (UMR-106) and renal (LLC-PK1) cells treated with 1alpha,25-dihydroxyvitamin D3,” Endocrine, vol. 17, no. 2, pp. 109–118, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Dhawan and S. Christakos, “Novel regulation of 25-hydroxyvitamin D3 24-hydroxylase (24(OH)ase) transcription by glucocorticoids: cooperative effects of the glucocorticoid receptor, C/EBPβ, and the vitamin D receptor in 24(OH)ase transcription,” Journal of Cellular Biochemistry, vol. 110, no. 6, pp. 1314–1323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. A. V. Khomenko, “Cholecalciferol hydroxylation in rat hepatocytes under the influence of prednisolone,” Ukrainskiǐ Biokhimicheskiǐ Zhurnal, vol. 85, no. 3, pp. 90–95, 2013. View at Google Scholar · View at Scopus
  27. I. Garcia-Delgado, S. Prieto, L. Gil-Fraguas, E. Robles, J. J. Rufilanchas, and F. Hawkins, “Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation,” Calcified Tissue International, vol. 60, no. 2, pp. 155–159, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Talalaj, L. Gradowska, E. Marcinowska-Suchowierska, M. Durlik, Z. Gaciong, and M. Lao, “Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients,” Transplantation Proceedings, vol. 28, no. 6, pp. 3485–3487, 1996. View at Google Scholar · View at Scopus
  29. H. A. Bischoff-Ferrari, B. Dawson-Hughes, E. Stöcklin et al., “Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity,” Journal of Bone and Mineral Research, vol. 27, no. 1, pp. 160–169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. K. D. Cashman, K. M. Seamans, A. J. Lucey et al., “Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults,” The American Journal of Clinical Nutrition, vol. 95, no. 6, pp. 1350–1356, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. T. C. B. Stamp, “Intestinal absorption of 25 hydroxycholecalciferol,” The Lancet, vol. 2, no. 7873, pp. 121–123, 1974. View at Google Scholar · View at Scopus
  32. L. Cianferotti, C. Cricelli, J. A. Kanis et al., “The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF),” Endocrine, 2015. View at Publisher · View at Google Scholar
  33. D. Price, A. Chisholm, T. van der Molen, N. Roche, E. V. Hillyer, and J. Bousquet, “Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness,” Current Allergy and Asthma Reports, vol. 11, no. 6, pp. 526–538, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. A. I. R. Garcia, “Recommendations on vitamin D and calcium supplements for adults in Spain,” Revista Espanola de Salud Publica, vol. 86, no. 5, pp. 461–482, 2012. View at Google Scholar · View at Scopus